期刊文献+

MicroRNAs participate in the cardioprotective activity of dexrazoxane against doxorubicin-induced cardiotoxicity 被引量:1

MicroRNAs participate in the cardioprotective activity of dexrazoxane against doxorubicin-induced cardiotoxicity
原文传递
导出
摘要 Background The co-administration of dexrazoxane (DEX) with each dose of doxoruhicin (Dox) is an efficient strategy to relieve Dox-induced cardiotoxicity, however, the mechanisms underlying the cardioprotective effect of DEX have not been well elucidated. MieroRNAs (miRNAs) are endogenous, small non-coding RNAs that negatively regulate gene expression in diverse biological and pathological processes. The aim of the present study was to investigate whether the certain cardiac miRNAs were involved in DOX-induced cardiotoxicity. Methods Male SD rats were randomized into five groups, including the 4-week (cumulative dose: 16 mg/kg) and the 8-week (cumulative dose: 32 mg/kg) Dox-treated groups, and the corresponding 4-week and 8-week Dox plus DEX-treated groups and the normal control group. Heart functions of the animals were detected by echocardiography. Quantitative real-time PCR was used to determine the expression of cardiac remodeling, apoptosis-related genes and mature micoRNAs of interest. Results The echocardiography detection showed that cardiac remodeling and impaired heart function were observed after 4-week and 8-week Dox treatment, and the cardiac remodeling and decreased ejection fraction (EF%) and fractional shortening (FS%) were efficiently rescued in the corresponding 4-week and 8-week Dox plus DEX-treated groups. The myocardial expression of Anp and CTGF mRNA was significantly upregulated by Dox treatment, but the upregulation of Anp and CTGF mHNA was blocked in the Dox plus DEX-treated groups. IGF-1 mRNA was significantly up-regulated in rat myocardium in Dox plus DEX-treated groups, with no significant changes of Bcl-2 and BAX mRNA expression. Mature miRNAs determination demonstrated that the myocardial miR-1 and -30e were significantly down-regulated and miR-21 and -208b were significantly up-regulated in Dox treatment groups, but the above miRNA dysregulation could be efficiently reversed after DEX treatment. Conclusions DEX could tune the microRNAs dysregulation in Dox-treated rat myocardium, miRNAs participated in the cardioprotective activity of DEX against Dox-induced cardiotoxicity. Background The co-administration of dexrazoxane (DEX) with each dose of doxoruhicin (Dox) is an efficient strategy to relieve Dox-induced cardiotoxicity, however, the mechanisms underlying the cardioprotective effect of DEX have not been well elucidated. MieroRNAs (miRNAs) are endogenous, small non-coding RNAs that negatively regulate gene expression in diverse biological and pathological processes. The aim of the present study was to investigate whether the certain cardiac miRNAs were involved in DOX-induced cardiotoxicity. Methods Male SD rats were randomized into five groups, including the 4-week (cumulative dose: 16 mg/kg) and the 8-week (cumulative dose: 32 mg/kg) Dox-treated groups, and the corresponding 4-week and 8-week Dox plus DEX-treated groups and the normal control group. Heart functions of the animals were detected by echocardiography. Quantitative real-time PCR was used to determine the expression of cardiac remodeling, apoptosis-related genes and mature micoRNAs of interest. Results The echocardiography detection showed that cardiac remodeling and impaired heart function were observed after 4-week and 8-week Dox treatment, and the cardiac remodeling and decreased ejection fraction (EF%) and fractional shortening (FS%) were efficiently rescued in the corresponding 4-week and 8-week Dox plus DEX-treated groups. The myocardial expression of Anp and CTGF mRNA was significantly upregulated by Dox treatment, but the upregulation of Anp and CTGF mHNA was blocked in the Dox plus DEX-treated groups. IGF-1 mRNA was significantly up-regulated in rat myocardium in Dox plus DEX-treated groups, with no significant changes of Bcl-2 and BAX mRNA expression. Mature miRNAs determination demonstrated that the myocardial miR-1 and -30e were significantly down-regulated and miR-21 and -208b were significantly up-regulated in Dox treatment groups, but the above miRNA dysregulation could be efficiently reversed after DEX treatment. Conclusions DEX could tune the microRNAs dysregulation in Dox-treated rat myocardium, miRNAs participated in the cardioprotective activity of DEX against Dox-induced cardiotoxicity.
出处 《South China Journal of Cardiology》 CAS 2012年第3期169-179,196,共12页 岭南心血管病杂志(英文版)
基金 supported by Grants from the National Natural Science Foundation of China (No. 81070102) Foundation of the Guangdong Provincial Science and Technology (20100309) the Natural Science Foundation of the Guangdong Province (Nos. 10151008004000035, S2011020005911)
关键词 CARDIOTOXICITY DOXORUBICIN DEXRAZOXANE APOPTOSIS cardiac remodeling MICRORNAS cardiotoxicity doxorubicin dexrazoxane apoptosis cardiac remodeling microRNAs
  • 相关文献

参考文献11

  • 1Brian B. Hasinoff,Eugene H. Herman.Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug?[J].Cardiovascular Toxicology.2007(2)
  • 2S. Ikeda,A. He,S. W. Kong.MicroRNA-1 negatively regulates expression of the hypertrophy-associated calmodulin and Mef2a genes[].Molecular and Cellular Biology.2009
  • 3Li Q,Song X W,Zou J,Wang G K,Kremneva E,Li X Q,Zhu N,Sun T,Lappalainen P,Yuan W J,Qin Y W,Jing Q.Attenuation of microRNA-1derepresses the cytoskeleton regulatory protein twinfilin-1toprovoke cardiac hypertrophy[].Journal of Cell Science.2010
  • 4Gewirtz D A.A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin[].Biochemical Pharmacology.1999
  • 5Minotti G,Menna P,Salvatorelli E,et al.Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity[].Pharmacological Reviews.2004
  • 6Pfaffl MW.A new mathematical model for relative quantification in real-time RT-PCR[].Nucleic Acids Research.2001
  • 7Bodley A,Leroy FL,Israel M,et al.DNA topoisomerase Ⅱ mediated interaction of doxorubicin and daunorubicin congeners with DNA[].Cancer Research.1989
  • 8Link,G,Tirosh,R,Pinson,A,Hershko,C.Role of iron in the potentiation of anthracycline cardiotoxicity: identification of heart cell mitochondria as a major site of iron-anthracycline interaction[].Journal of Laboratory and Clinical Medicine.1996
  • 9Miranda CJ,Makui H,Soares RJ etc.Hfe deficiency increases susceptibility to cardiotoxicity and exacerbates changes in iron metabolism induced by doxorubicin[].Blood.2003
  • 10Cvetkovi RS,Scott LJ.Dexrazoxane:a review of its use forcardiopro tection during anthracycline chemotherapy[].Drugs.2005

同被引文献1

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部